Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences EV-based Diagnostics, Delivery & Therapeutics

Dominique PV de Kleijn's Biography



Dominique PV de Kleijn, Professor Experimental Vascular Surgery, Professor Netherlands Heart Institute, University Medical Center Utrecht, The Netherlands

Prof. Dr. Dominique PV de Kleijn is a molecular biologist and chemist, and professor of Experimental Vascular Surgery at UMC Utrecht and professor at the Netherlands Heart Institute. From 2012 to 2016, he was Research Professor of Surgery at NUS/NUHS and preclinical director of the Cardiovascular Research Institute (CVRI) Singapore. He was until 2016 professor of Cardiovascular Immunology and co-chair of Experimental Cardiology at UMC Utrecht. Since 1997 he is coordinating cardiovascular research from basic science, animal myocardial infarction and atherosclerotic studies (mouse and pig) towards clinical biobanking studies. His research interests are: The innate immune system in cardiovascular disease and atherosclerosis & Biomarkers predictive for primary & secondary events with a focus on plasma extracellular vesicles. He has more than 200 publications and a H-factor of 68.

Dominique PV de Kleijn Image

Plasma Extracellular Vesicle Sub-fractions as Biomarker Source For Cardiovascular Disease

Monday, 17 February 2020 at 14:30

Add to Calendar ▼2020-02-17 14:30:002020-02-17 15:30:00Europe/LondonPlasma Extracellular Vesicle Sub-fractions as Biomarker Source For Cardiovascular DiseaseEV-based Diagnostics, Delivery and Therapeutics in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Cardiovascular Disease (CVD) is with the cardiovascular events of Ischemic Heart Disease and Stroke, the number 1 and 2 cause of death in the world and expect to increase especially in Asia. Ischemic heart disease (IHD) comprises 3 entities: stable coronary artery disease (SCAD), unstable angina (UA) and myocardial infarction (MI). Because IHD is associated with an increased risk of adverse clinical events such as heart failure and death, early recognition of IHD is of utmost importance. However, to diagnosis SCAD is challenging, as many patients present with atypical symptoms. Troponins are the main diagnostic tool for detection of MI. Blood biomarkers for SCAD (typically causing stable angina) and UA, however, are not available. These diagnoses frequently require hospital visits/admissions for time-consuming and costly (non)invasive tests. We use plasma extracellular vesicle protein content of vesicles from plasma sub-fractions as an accurate source for early diagnosis of SCAD. This plasma sub-fraction technology is also used for prognosis of a second MI or stroke to identify the high risk patient that can be treated with more intensive and often more costly medication.


Add to Calendar ▼2020-02-17 00:00:002020-02-18 00:00:00Europe/LondonEV-based Diagnostics, Delivery and TherapeuticsEV-based Diagnostics, Delivery and Therapeutics in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com